Captrust Financial Advisors Decreases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Captrust Financial Advisors trimmed its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 22.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 766 shares of the medical research company’s stock after selling 226 shares during the quarter. Captrust Financial Advisors’ holdings in Bio-Rad Laboratories were worth $256,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Avior Wealth Management LLC lifted its stake in Bio-Rad Laboratories by 3.3% in the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after purchasing an additional 32 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the last quarter. Capital Advisors Ltd. LLC increased its holdings in shares of Bio-Rad Laboratories by 193.8% during the 2nd quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after buying an additional 62 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Bio-Rad Laboratories by 9.5% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company’s stock worth $259,000 after buying an additional 82 shares during the last quarter. Finally, Creative Planning increased its holdings in shares of Bio-Rad Laboratories by 6.0% during the 3rd quarter. Creative Planning now owns 1,632 shares of the medical research company’s stock worth $546,000 after buying an additional 93 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Stock Down 1.1 %

Bio-Rad Laboratories stock opened at $336.28 on Monday. Bio-Rad Laboratories, Inc. has a fifty-two week low of $262.12 and a fifty-two week high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The firm has a 50 day moving average price of $341.35 and a 200 day moving average price of $321.29. The company has a market capitalization of $9.41 billion, a PE ratio of -12.30 and a beta of 0.90.

Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The firm had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same quarter last year, the firm earned $2.33 EPS. The firm’s revenue for the quarter was up 2.8% on a year-over-year basis. Research analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BIO. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Royal Bank of Canada raised their price target on shares of Bio-Rad Laboratories from $369.00 to $481.00 and gave the stock an “outperform” rating in a report on Monday, December 9th. Finally, Wells Fargo & Company began coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They set an “equal weight” rating and a $340.00 price target for the company. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Bio-Rad Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $394.20.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.